WT1 and cancer: WT1, which is overexpressed in most adult and pediatric patients with acute leukemia, chronic myelocyte leukemia, and myelodysplastic syndrome [6], is considered most promising among 75 TAAs as a target for cancer vaccines and/or T cell adaptive immunotherapy [7].